Abstract
Vascular risk factors and atherosclerosis are critically involved in dementia development of both vascular and Alzheimer’s type. However, the exact mechanisms linking atherosclerosis and the development of Alzheimer’s disease (AD) are still unknown. As platelet activation and adhesion on vascular wall is the first step of vascular inflammation and atherosclerosis, it appears tempting to hypothesize that platelets could be the link between vascular risk factors/ atherosclerosis and AD. In recent years, much work has been accomplished to elucidate the role of platelets in AD. The present review will summarize and highlight the latest findings of this research area and provide novel insight and understanding in the association between platelet activation and AD.
Keywords: Alzheimer’s disease, platelet activation, treatment targets, vascular risk factors, atherosclerosis, hyperlipidaemia, hypertension, type 2 diabetes, MCI, serotonin
Current Vascular Pharmacology
Title:Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Volume: 10 Issue: 5
Author(s): Christoph Laske, Kateryna Sopova and Konstantinos Stellos
Affiliation:
Keywords: Alzheimer’s disease, platelet activation, treatment targets, vascular risk factors, atherosclerosis, hyperlipidaemia, hypertension, type 2 diabetes, MCI, serotonin
Abstract: Vascular risk factors and atherosclerosis are critically involved in dementia development of both vascular and Alzheimer’s type. However, the exact mechanisms linking atherosclerosis and the development of Alzheimer’s disease (AD) are still unknown. As platelet activation and adhesion on vascular wall is the first step of vascular inflammation and atherosclerosis, it appears tempting to hypothesize that platelets could be the link between vascular risk factors/ atherosclerosis and AD. In recent years, much work has been accomplished to elucidate the role of platelets in AD. The present review will summarize and highlight the latest findings of this research area and provide novel insight and understanding in the association between platelet activation and AD.
Export Options
About this article
Cite this article as:
Laske Christoph, Sopova Kateryna and Stellos Konstantinos, Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784657
DOI https://dx.doi.org/10.2174/157016112801784657 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Current Molecular Medicine Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites
Current Alzheimer Research Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease
Current Medical Imaging On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Small Molecules and Alzheimer’s Disease: Misfolding, Metabolism and Imaging
Current Alzheimer Research Abnormal Sleep Behaviours Across the Spectrum of Alzheimer’s Disease Severity: Influence of APOE Genotypes and Lewy Bodies
Current Alzheimer Research Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research Modulation of Alzheimers Amyloidosis by Statins: Mechanisms of Action
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design